On the correction of mimic wrinkles and age-related changes in the upper third of the face (forehead, glabella, eyebrows, eyes, nose) using botulinum toxin type A.

Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxin A) for the Treatment of Moderate to Severe Glabellar Lines.

Mesotherapy is a method of administering medications intradermally in very low doses, to achieve both a pharmacological effect and a physical stimulation effect.

Many people have noticed that lately the effect of Botox has become shorter. Previously, the results lasted about six months, but now only around three. Is it tolerance? Are cosmetologists diluting the product more? Has the composition of the drug changed?

Today, the professional market offers an entire family of botulinum toxin–containing drugs, but they are not “twins” and have different safety and efficacy profiles, as well as differences related to production, composition, and application protocols.

Until recently, plastic surgery was based on a simple principle: signs of aging were eliminated by excising skin, fat, fascia, and muscle tissue, followed by tightening of the remaining tissues. But what about now? What changes have occurred in the approach to rejuvenation?

The primary goal of cosmetology is the prevention and correction of age-related skin changes. And today, it is no secret that the combination of various techniques, each affecting the pathogenetic mechanisms of aging in different ways, can work wonders.

In recent years, botulinum toxin preparations have gained popularity as a means of smoothing out expression lines — wrinkles caused by excessive activity of the facial muscles. But is Botox really dangerous, and what do we actually know about it?

An in-depth analysis of the lack of effect of botulinum toxin type A treatment and the decline in its efficacy with long-term use. Causes of nonresponse or reduced effect with prolonged administration.

Xeomin has been used in clinical practice for more than 10 years, with over 127,000 people having received injections of this drug, and to date, not a single patient has been identified who failed to show a secondary clinical response.